| 1. |
- Bakker, D. C. E., et al.
(författare)
-
An update to the surface ocean CO2 atlas (SOCAT version 2)
- 2014
-
Ingår i: Earth System Science Data. - : Copernicus GmbH. - 1866-3508 .- 1866-3516. ; 6:1, s. 69-90
-
Tidskriftsartikel (refereegranskat)abstract
- The Surface Ocean CO2 Atlas (SOCAT), an activity of the international marine carbon research community, provides access to synthesis and gridded fCO2 (fugacity of carbon dioxide) products for the surface oceans. Version 2 of SOCAT is an update of the previous release (version 1) with more data (increased from 6.3 million to 10.1 million surface water fCO 2 values) and extended data coverage (from 1968-2007 to 1968-2011). The quality control criteria, while identical in both versions, have been applied more strictly in version 2 than in version 1. The SOCAT website (http://www.socat.info/) has links to quality control comments, metadata, individual data set files, and synthesis and gridded data products. Interactive online tools allow visitors to explore the richness of the data. Applications of SOCAT include process studies, quantification of the ocean carbon sink and its spatial, seasonal, year-to-year and longerterm variation, as well as initialisation or validation of ocean carbon models and coupled climate-carbon models. © Author(s) 2014. CC Attribution 3.0 License.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Gronseth, Rune, et al.
(författare)
-
Predictors of dyspnoea prevalence : results from the BOLD study
- 2014
-
Ingår i: European Respiratory Journal. - : European Respiratory Society (ERS). - 0903-1936 .- 1399-3003. ; 43:6, s. 1610-1620
-
Tidskriftsartikel (refereegranskat)abstract
- Dyspnoea is a cardinal symptom for cardiorespiratory diseases. No study has assessed worldwide variation in dyspnoea prevalence or predictors of dyspnoea. We used cross-sectional data from population-based samples in 15 countries of the Burden of Obstructive Lung Disease (BOLD) study to estimate prevalence of dyspnoea in the full sample, as well as in an a priori defined low-risk group (few risk factors or dyspnoea-associated diseases). Dyspnoea was defined by the modified Medical Research Council questions. We used ordered logistic regression analysis to study the association of dyspnoea with site, sex, age, education, smoking habits, low/high body mass index, self-reported disease and spirometry results. Of the 9484 participants, 27% reported any dyspnoea. In the low-risk subsample (n = 4329), 16% reported some dyspnoea. In multivariate analyses, all covariates were correlated to dyspnoea, but only 13% of dyspnoea variation was explained. Females reported more dyspnoea than males (odds ratio similar to 2.1). When forced vital capacity fell below 60% of predicted, dyspnoea was much more likely. There was considerable geographical variation in dyspnoea, even when we adjusted for known risk factors and spirometry results. We were only able to explain 13% of dyspnoea variation.
|
|
| 5. |
- Lauvset, S. K., et al.
(författare)
-
Annual and seasonal fCO(2) and air-sea CO2 fluxes in the Barents Sea
- 2013
-
Ingår i: Journal of Marine Systems. - : Elsevier BV. - 0924-7963. ; 113-114, s. 62-74
-
Tidskriftsartikel (refereegranskat)abstract
- The Barents Sea is the strongest CO2 sink in the Arctic region, yet estimates of the air-sea CO2 flux in this area show a large span reflecting uncertainty as well as significant variability both seasonally and regionally. Here we use a previously unpublished data set of seawater CO2 fugacity (fCO(2)), and map these data over the western Barents Sea through multivariable linear regressions with SeaWiFS/MODIS remote sensing and TOPAZ model data fields. We find that two algorithms are necessary in order to cover the full seasonal cycle, mainly because not all proxy variables are available for the entire year, and because variability in fCO(2) is driven by different mechanisms in summer and winter. A comprehensive skill assessment indicates that there is a good overall correspondence between observations and predictions. The algorithms are also validated using two independent data sets, with good results. The gridded fCO(2) fields reveal tight links between water mass distribution and fCO(2) in all months, and particularly in winter. The seasonal cycle show peaks in the total air-sea CO2 influx in May and September, caused by respectively biological drawdown of CO2 and low sea ice concentration leaving a large open water area. For 2007 the annual average air-sea CO2 flux is -48 +/- 5 gC m(-2), which is comparable to previous estimates. (C) 2013 Elsevier B.V. All rights reserved.
|
|
| 6. |
- Macsali, F., et al.
(författare)
-
Menstrual Cycle and Respiratory Symptoms in a General Nordic-Baltic Population
- 2013
-
Ingår i: American Journal of Respiratory and Critical Care Medicine. - 1073-449X .- 1535-4970. ; 187:4, s. 366-373
-
Tidskriftsartikel (refereegranskat)abstract
- Rationale :Thereislittleknowledgeofvariationsinrespiratorysymp- tomsduringthemenstrualcycleinageneralpopulation,andpoten- tial modifying factors are not investigated. Objectives : To investigate menstrual cycle variation in respiratory symptomsinalargegeneralpopulation,usingchronobiologymeth- odology, and stratifying by body mass index (BMI), smoking, and asthma status. Methods : A total of 3,926 women with regular cycles less than or equal to 28 days and not taking exogenous sex hormones answered a postalquestionnaire regarding the first day of their last menstrua- tion and respiratory symptoms in the last 3 days. Moving 4-day meanswerecomputedto smoothunevenrecordsof dailysampling; best-fitting 28-day composite cosine curves were applied to each time series to describe rhythmicity. Measurements and Main Results : Significant rhythmic variations over themenstrualcyclewerefoundineachsymptomforallsubjectsand subgroups. Wheezing was higher on cycle Days 10–22, with a mid- cycle dip near the time of putative ovulation (approximately Days 14–16) in most subgroups. Shortness of breath was higher on days 7–21,withadipjustbeforemidcycleinmanysubgroups.Coughwas higher just after putative ovulation for subjects with asthma, BMI greater than or equal to 23 kg/m 2 , and smokers, or just before ovu- lation and menses onset for low symptomatic subgroups. Conclusions : Respiratory symptoms varied significantly during the menstrual cycle and were most frequent from the midluteal to mid- follicular stages, often with a dip near the time of ovulation. The patternsvariedbyBMI,smoking,andasthmastatus.Theserelations linkrespiratorysymptomswithhormonalchangesthroughthemen- strual cycle and imply a potential for individualized chronotherapy for respiratory diseases.
|
|
| 7. |
- Metzl, Nicolas, et al.
(författare)
-
Recent acceleration of the sea surface fCO2 growth rate in the North Atlantic subpolar gyre (1993–2008) revealed by winter observations
- 2010
-
Ingår i: GLOBAL BIOGEOCHEMICAL CYCLES. - 0886-6236. ; 24
-
Tidskriftsartikel (refereegranskat)abstract
- Recent studies based on ocean and atmospheric carbon dioxide (CO2) observations, suggesting that the ocean carbon uptake has been reduced, may help explain the increase in the fraction of anthropogenic CO2 emissions that remain in the atmosphere. Is it a response to climate change or a signal of ocean natural variability or both? Regional process analyses are needed to follow the ocean carbon uptake and to enable better attributions of the observed changes. Here, we describe the evolution of the surface ocean CO2 fugacity (fCO2 oc) over the period 1993–2008 in the North Atlantic subpolar gyre (NASPG). This analysis is based primarily on observations of dissolved inorganic carbon (DIC) and total alkalinity (TA) conducted at different seasons in the NASPG between Iceland and Canada. The fCO2 oc trends based on DIC and TA data are also compared with direct fCO2 measurements obtained between 2003 and 2007 in the same region. During winters 1993–2003, the fCO2 oc growth rate was 3.7 (±0.6) matm yr−1, higher than in the atmosphere, 1.8 (±0.1) matm yr−1. This translates to a reduction of the ocean carbon uptake primarily explained by sea surface warming, up to 0.24 (±0.04) °C yr−1. This warming is a consequence of advection of warm water northward from the North Atlantic into the Irminger basin, which occurred as the North Atlantic Oscillation (NAO) index moved into a negative phase in winter 1995/1996. In winter 2001–2008, the fCO2 oc rise was particularly fast, between 5.8 (±1.1) and 7.2 (±1.3) matm yr−1 depending on the region, more than twice the atmospheric growth rate of 2.1 (±0.2) matm yr−1, and in the winter of 2007–2008 the area was supersaturated with CO2. As opposed to the 1990s, this appears to be almost entirely due to changes in seawater carbonate chemistry, the combination of increasing DIC and decreasing of TA. The rapid fCO2 oc increase was not only driven by regional uptake of anthropogenic CO2 but was also likely controlled by a recent increase in convective processes‐vertical mixing in the NASPG and cannot be directly associated with NAO variability. The fCO2 oc increase observed in 2001–2008 leads to a significant drop in pH of −0.069 (±0.007) decade−1.
|
|
| 8. |
- Parker, C., et al.
(författare)
-
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- 2013
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 369:3, s. 213-223
-
Tidskriftsartikel (refereegranskat)abstract
- Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. Methods In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. Results At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. Conclusions In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.)
|
|
| 9. |
|
|
| 10. |
|
|
